Research Article
Low-Dose Ibutilide Combined with Catheter Ablation of Persistent Atrial Fibrillation: Procedural Impact and Clinical Outcome
| | | Total () | CPVI responders () | LA substrate responders () | Nonresponders () | value |
| | Age, years | 63 ± 10 | 62 ± 12 | 63 ± 9 | 63 ± 10 | 0.913 | | Male, (%) | 85 (63.0) | 26 (55.3) | 31 (59.6) | 28 (77.8) | 0.090 | | BMI | 26 ± 5 | 26 ± 5 | 26 ± 5 | 27 ± 3 | 0.873 | | Hypertension, (%) | 95 (70.4) | 29 (61.7) | 38 (73.1) | 25 (69.4) | 0.470 | | Underlying heart disease, (%) | 25 (18.5) | 9 (19.1) | 12 (23.1) | 4 (11.1) | 0.361 | | Diabetes mellitus, (%) | 31 (23.0) | 6 (12.8) | 18 (34.6) | 7 (19.4) | 0.030 | | History of stroke, (%) | 13 (9.6) | 3 (6.4) | 8 (15.4) | 2 (5.6) | 0.198 | | Atrial fibrillation duration | | | | | | | Duration (month) | 14 ± 18 | 8 ± 14 | 13 ± 14 | 23 ± 24 | 0.001 | | Short lasting/long lasting/uncertain (n) | 76/40/19 | 32/7/8 | 26/19/7 | 18/14/4 | 0.1064 | | CHA2DS2-VASc score | 2.4 ± 1.5 | 2.3 ± 1.5 | 2.6 ± 1.5 | 2.3 ± 1.5 | 0.402 | | HAS-BLED score | 1.3 ± 0.8 | 1.2 ± 0.8 | 1.4 ± 0.8 | 1.3 ± 0.6 | 0.352 | | LA volume (ml) | 123 ± 29 | 111 ± 24 | 124 ± 28 | 138 ± 29 | 0.000 | | Left ventricular diastolic diameter (mm) | 48 ± 5 | 47 ± 5 | 48 ± 5 | 50 ± 5 | 0.036 | | Left ventricular ejection fraction (%) | 62 ± 10 | 62 ± 10 | 62 ± 10 | 62 ± 8 | 0.963 |
|
|
Values are presented as mean ± SD or as (%). CPVI: circumferential pulmonary vein isolation; LA: left atrium; BMI: body mass index. |
